IKZF5
IKZF5 (Ikaros Family Zinc Finger 5) functions as a transcriptional regulator in lymphocyte development, modulating gene expression critical for immune cell differentiation[1][2]. Mechanistically, IKZF5 interacts with chromatin remodeling complexes to influence T and B cell lineage commitment, thereby affecting hematopoietic homeostasis[2][3]. In disease models, dysregulation of IKZF5 has been associated with immunodeficiencies and hematological malignancies, including acute lymphoblastic leukemia[4][5]. Compared with other Ikaros family isoforms, IKZF5 exhibits unique DNA-binding specificity and distinct N-terminal zinc finger arrangements, enabling selective regulation of target genes[2][3]. Experimental applications have leveraged isoform-specific knockdown and overexpression systems to dissect IKZF5-mediated transcriptional networks in vitro and in vivo[5]. Small-molecule modulation of IKZF5 remains under investigation; however, post-translational modification-targeted strategies offer potential for isoform-selective pharmacological interventions[6][7]. The selective activity of these interventions may provide insights into disease-specific gene regulatory circuits without broadly affecting related isoforms. Therefore, understanding the structural and functional distinctions of IKZF5 is essential for designing precise experimental models and therapeutic approaches in immunology and oncology research[3][5][6].
References:
- [1]. Kitamura N, et al. Isoform-Selective NFAT Inhibitor: Potential Usefulness and Development. Int J Mol Sci. 2021 Mar 8;22(5):2725. [Content Brief]
- [2]. Willems HMG, et al. Identification of ARUK2002821 as an isoform-selective PI5P4Kα inhibitor. RSC Med Chem. 2023 Apr 17;14(5):934-946. [Content Brief]
- [3]. Schihada H, et al. Isoforms of GPR35 have distinct extracellular N-termini that allosterically modify receptor-transducer coupling and mediate intracellular pathway bias. J Biol Chem. 2022 Sep;298(9):102328. [Content Brief]
- [4]. Downey GP, et al. Chemotactic peptide-induced activation of MEK-2, the predominant isoform in human neutrophils. Inhibition by wortmannin. J Biol Chem. 1996 Aug 30;271(35):21005-1011. [Content Brief]
- [5]. Thiele M, et al. OxMIF: a druggable isoform of macrophage migration inhibitory factor in cancer and inflammatory diseases. J Immunother Cancer. 2022 Sep;10(9):e005475. [Content Brief]
- [6]. Meng F, et al. Drug design targeting active posttranslational modification protein isoforms. Med Res Rev. 2021 May;41(3):1701-1750. [Content Brief]
- [7]. Suzuki T. Explorative study on isoform-selective histone deacetylase inhibitors. Chem Pharm Bull (Tokyo). 2009 Sep;57(9):897-906. doi: 10.1248/cpb.57.897. PMID: 19721249. et al. Explorative study on isoform-selective histone deacetylase inhibitors. Chem Pharm Bull (Tokyo). 2009 Sep;57(9):897-906. [Content Brief]
